drugset / Trial / NCT05740956
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.
Timeline
- Start
- 2023-06-09
- Primary completion
- 2026-04-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10502 | Unknown | — | Oral |